MerusCase - Technology for Attorneys
No more bulky files lying around, and no more having to spend 15 minutes looking for a file: everything we need is easily accessible in Merus. We have used other case management systems, but Merus is …
Pipeline | Merus
Merus has exclusively licensed Betta Pharmaceuticals Co. Ltd. to develop and potentially commercialize MCLA-129 in China, while Merus retains full rights ex-China.
Genmab completes acquisition of Merus and delists shares from ...
2 days ago · Genmab A/S has completed its acquisition of Merus N.V. (NASDAQ:MRUS), according to a press release statement based on a recent SEC filing. The transaction was finalized Monday through …
Genmab Announces Completion of Tender Offer for Outstanding ...
Dec 11, 2025 · Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Dec 12, 2025 at 7:35 AM CET …
Merus (MRUS) Stock Price & Overview
2 days ago · A detailed overview of Merus N.V. (MRUS) stock, including real-time price, chart, key statistics, news, and more.
Genmab to Acquire Merus and Novel Advanced Cancer Prospect ...
Oct 1, 2025 · Genmab intends to acquire all the shares of Merus and its late-stage, first-in-class cancer drug petosemtamab for approximately $8 billion. Petosemtamab, with pembrolizumab, is in Phase III …
Merus N.V. Announces Pricing of Public Offering of Common
Jun 4, 2025 · Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ®.